SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

This article was originally published here

“We are pleased to be awarded this additional contract scope, which we believe is a reflection of the compelling science that supports SAB-185’s potential in COVID-19, as well

The post SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply